key: cord-0020247-0ltjie9t
authors: Li, Qingxin; Kang, Congbao
title: Structure and Dynamics of Zika Virus Protease and Its Insights into Inhibitor Design
date: 2021-08-19
journal: Biomedicines
DOI: 10.3390/biomedicines9081044
sha: cbe9842bbd7cbdf83c493fe15a380a6f82bdc5ce
doc_id: 20247
cord_uid: 0ltjie9t

Zika virus (ZIKV)—a member of the Flaviviridae family—is an important human pathogen. Its genome encodes a polyprotein that can be further processed into structural and non-structural proteins. ZIKV protease is an important target for antiviral development due to its role in cleaving the polyprotein to release functional viral proteins. The viral protease is a two-component protein complex formed by NS2B and NS3. Structural studies using different approaches demonstrate that conformational changes exist in the protease. The structures and dynamics of this protease in the absence and presence of inhibitors were explored to provide insights into the inhibitor design. The dynamic nature of residues binding to the enzyme cleavage site might be important for the function of the protease. Due to the charges at the protease cleavage site, it is challenging to develop small-molecule compounds acting as substrate competitors. Developing small-molecule compounds to inhibit protease activity through an allosteric mechanism is a feasible strategy because conformational changes are observed in the protease. Herein, structures and dynamics of ZIKV protease are summarized. The conformational changes of ZIKV protease and other proteases in the same family are discussed. The progress in developing allosteric inhibitors is also described. Understanding the structures and dynamics of the proteases are important for designing potent inhibitors.

Zika virus (ZIKV) belongs to Flaviviridae, which contains other important human pathogens, such as dengue, West Nile, yellow fever, and Japanese encephalitis viruses. ZIKV was first isolated in 1947; the viral infection usually causes mild symptoms, which might not require medical treatment [1] . ZIKV infection received attention in recent years, as it was found to transmit from human-to-human and it could result in serious diseases, such as microcephaly in newborns [2] and Guillain-Barré syndrome in adults [3, 4] . An outbreak occurred during 2015-2016 and over 2 million people were affected [4] [5] [6] [7] . Effort has been made to develop antivirals and vaccines to combat the virus while no specific medical treatment is available [8] [9] [10] [11] .

ZIKV is a positive-sense RNA virus whose genome has one open reading frame [12, 13] . The polyprotein encoded by the viral genome is cleaved by both host and viral proteases to release functionally structural and non-structural proteins. ZIKV genome encodes three structural proteins, C, PrM/M, and E [14, 15] , and seven non-structural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. The amino acid sequences of ZIKV proteins exhibit high sequence homology with those of other flaviviruses, such as dengue and West Nile viruses. The functions of viral proteins can be predicted based on the available knowledge of flaviviruses. Among these non-structural proteins, only NS3 and NS5 of flaviviruses possess enzymatic activities [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . The other proteins are indispensable for viral invasion, assembly, and replication through interacting with cell membrane, host proteins, or viral 

The protease of ZIKV is a serine protease with a catalytic triad formed by three residues, H51, D75, and S135, in the N-terminal region of NS3, whose C-terminal domain contains helicase and NTPase activities [33] . Unlike other serine proteases, which only contain a single polypeptide chain, the flavivirus protease, such as the ZIKV protease, is formed by NS2B-a membrane protein with four helices embedded in the cell membrane and the N-terminal region of NS3 containing the residues for peptide cleavage [48, [74] [75] [76] [77] [78] [79] . Studies show that the hydrolysis of the peptide bond requires the formation of NS2B-NS3 complex [67, 80, 81] . Although NS2B does not contain residues responsible for substrate cleavage and its transmembrane domains are not critical for the enzymatic activity, it has several roles indispensable to the functioning of viral protease. First, NS2B is critical for the folding of NS3 as NS3 alone is insoluble or unstructured when it is expressed in bacterial cells. NS2B binds tightly with NS3 through a hydrophilic region between the second and the third transmembrane helix [67, 80, 81] . Second, the molecular interaction between NS2B and the substrate is critical for the enzymatic activity, as recombinant protease constructs lacking the substrate-binding region from NS2B exhibited almost no protease activity. Lastly, NS2B is located on the cell membrane [82] . The NS2B-NS3 complex makes the protease approachable to other cleavage sites, which are in close proximity to cell membranes. The non-structural proteins of the virus form a replication complex on the ER membrane [83] [84] [85] [86] [87] . The location of NS2B on the membrane is critical for protease activity, which makes NS3 perform its other functions (important for viral replication). Therefore, both NS2B and NS3 are important targets for developing antivirals [88] .

To explore the structure of viral proteases, different constructs were made for in vitro studies [89] . NS2B demonstrated to have four transmembrane helices while the folding of these helices is not defined in the structural study due to lack of long-range restraints [71, 90] . The structure of the full-length NS2B fused with NS3 was not obtained, as the folding of the entire NS2B requires the presence of membrane systems and is challenging for crystallization. Studies of crystal structures on most flavivirus proteases used an artificial construct in which the hydrophilic NS2B peptide between transmembrane helices 2 and 3 was linked with the NS3 protease region (NS3pro) via a G 4 SG 4 linker [91] [92] [93] . This construct was overexpressed and purified from bacterial cells for biochemical and structural analysis in the absence of membrane systems [80, 81, 94] . Structures of this construct reveal that protease exists in open and closed conformations under different conditions [67, 95] . The folding of NS3 is almost identical in both conformations while the C-terminal portion of the NS2B region exhibits various conformations [87] . Structural studies show that proteases of dengue West Nile virus and ZIKV are very similar and adopt a chymotrypsin-like structure with two β-barrels. NS3 harbors the catalytic triad formed by three residues (H51, D74, and S135) [96] . Approximately 40 amino acids from NS2B form a complex with NS3pro. The N-terminal region of the NS2B peptide forms a β-strand and integrates with the N-terminal domain of NS3, and the binding affinity is very low, as NS2B and NS3pro always form a complex when they are co-expressed in bacterial cells [97, 98] . It has been noted that the free 40-residue NS2B peptide was observed when the NS2B-NS3pro complex was purified for structural studies [57] . There is no cell-based study to show the presence of free NS2B. It might be useful for exploring the novel function of NS2B [99] [100] [101] . The C-terminal part of the 40-residue NS2B peptide forms a β-hairpin structure, wrapping around the active site of the protease to form the active-closed conformation in which NS2B participates in formation of the S2 pocket, which is crucial for substrate-binding and catalytic activity [57] [58] [59] [60] [61] 102] . A structural study also reveals a salt bridge between the side chain of P2 residue and D83 of NS2B while such an interaction was not observed in structures of dengue and West Nile proteases [54] . In the absence of a substrate or an inhibitor, the C-terminal region of NS2B can stay away from the active site to form the inactive-open conformation in a construct containing the G 4 SG 4 linker [56] (Figure 2 ). Further NMR studies demonstrate that both conformations are present in this construct and inhibitors/substrates are able to increase the population of the closed conformation in solution [62, 63, 65, 66, [103] [104] [105] . Another NMR study demonstrated that removal of the glycine-rich linker in the dengue protease can also increase the population of the closed conformation in solution [98] . In the study, the hydrophilic NS2B region, comprising approximately 40 residues, was co-expressed with NS3pro. The purified dengue protease exists mainly in the closed conformation in solution as evidenced by the paramagnetic study. The similar construct of ZIKV protease was studied and the result shows that the closed conformation is predominantly present while conformational exchanges exist for some residues at the interface of NS2B and NS3. Inhibitor or substrate binding to protease eliminates such exchanges [57] [58] [59] [60] . The structural studies on the three structures provide useful information for designing inhibitors ( Figure 2 ). The boundary between NS2B and NS3 is highlighted with a red cycle. NS2B cofactor and NS3pro are shown in green and yellow, respectively. The dynamic nature of substrate is critical for its dissociation with protease, which is critical for releasing other proteins.

The structures of ZIKV protease have been well characterized using three constructs namely gZiPro with a G 4 SG 4 linker, eZiPro with a native protease cleavage site containing P1 to P4 residues, and bZiPro without any linker between NS2B cofactor region and NS3pro [57, 58, 106] . Both bZiPro and eZiPro are in the closed conformation and the Cterminal region of the 40-residue NS2B peptide is well folded. In bZiPro, the active site is open for substrate binding. In eZiPro structure, P1-P4 residues occupy the active site and exhibit interactions with NS2B while the protease is still active and binds to inhibitors [57, 58] . The open structure was observed in gZiPro and the inhibitor bound gZiPro exists in the closed conformation [54, 107] . Several studies demonstrate that bZiPro is very suitable for understanding protease and inhibitor interactions, as the substratebinding pocket is accessible to various types of inhibitors [57, 59, 60, 102] . Although the active site of eZiPro is occupied by its native substrate, this construct is close to the native protease under physiological conditions. A study also shows that the hit rate of fragment screening using eZiPro is higher than that of bZiPro [102] . The artificial linker in gZiPro affects the chemical environment of quite a few residues, while it is still useful for structural and biochemical studies [61, 108] . All constructs are very useful for developing protease inhibitors, while they are artificial constructs lacking the NS2B transmembrane regions, which can restrict the motion of the hydrophilic region [33, 63, 109, 110] .

The crystal structures of flaviviruses provide insight into drug design and a clue to evaluate whether an inhibitor can exhibit activity against other viral proteases in this family. The current ZIKV protease inhibitors also exhibit activity against proteases of dengue and West Nile viruses. To evaluate whether an inhibitor has a broad spectrum against different viruses in this family, analyzing protease sequences and structures will be a feasible strategy.

Druggability is a term in drug discovery referring to the likelihood of developing a small-molecule compound, which can modulate a target [111, 112] . Druggability of a target can also be interpreted as the fact that a binding site is present for forming tight interactions with a small-molecule compound. It is important to estimate the successful rate of a drug discovery project. There are several ways to predict druggability of a target. The structural study on a target is one of the efficient strategies to analyze druggability [113, 114] . A smallmolecule drug is usually hydrophobic with a tendency to interact with a hydrophobic surface. Therefore, analyzing the surface charges of a target that affect the hydrophobicity of the pocket can be utilized as one of the criteria to evaluate the druggability [115] . Proteases of flaviviruses, such as ZIKV, dengue, and West Nile virus recognize a sequence with positively charges residues such as Arg and Lys at P1 and P2 position [116] . The S1 and S2 pockets of the protease active site are negatively charged ( Figure 3) . Therefore, the druggability of the active side of ZIKV protease is very low [117] . To develop smallmolecule inhibitors, other druggable sites of ZIKV protease need to be identified [118, 119] . Structural studies reveal the presence of the open and closed conformations, making it possible to develop small-molecule inhibitors through allosteric mechanisms, such as stabilizing the open/inactive conformation or inducing conformational changes of NS2B [74, 120] . The TGKR residues are shown in different color. The surface charge figure was made using PyMOL (www.pymol.org (accessed on 3 August 2018)). Surface areas with positive charge, negative charge, and no charge are shown in blue, red, and white, respectively. The substrate-binding site is negative charged, suggesting the challenges of developing small molecule inhibitors, which prefer interacting with a hydrophobic surface.

The charges in the protease active site make developing small molecules challenging while the progress made in the development potent peptidic and allosteric inhibitors still show that it is feasible to develop protease inhibitors for clinical applications.

The native form of ZIKV protease contains four components-the transmembrane helices of NS2B, the 40-residues NS2B sequence (cofactor region) interacting with NS3pro, the protease cleavage site, and NS3pro ( Figure 2 ). The structural study has not yet been carried out for the native form of ZIKV protease [110, 121, 122] . Protein dynamics and conformational changes have been analyzed using artificial constructs and computational techniques [64, 123, 124] . The first NMR study on West Nile protease was carried out to understand the open and closed conformations [62] . In the study, exchanges were observed in the protease and inhibitor binding to protease stabilized the closed conformation. As the protease cleavage site is present in the native protease, the closed conformation was proposed to be utilized in structure-based drug design [65, 66] . A careful study was carried out on dengue protease to access the folding of the protease in solution. Both open and closed conformations were observed in solution [103] . Similar to West Nile protease, inhibitor binding to dengue protease reduces the population of the closed conformation [63] . Another NMR study using an unlinked dengue protease demonstrated that the closed conformation was predominant in solution [98] (Figure 4 ). In the unlinked protease-bZiPro, the protease exists in the closed conformation while exchanges are also present for the residues at the C-terminal part of NS2B peptide and some residues from NS3 ( Figure 4 ). In the presence of substrate peptides, the exchanges at the NS2B and NS3pro were suppressed (Figure 4) . A crystal structure of eZiPro captured the molecular interactions between P1-P4 residues and viral protease [58] . A follow-up NMR study demonstrates that the P1-P4 residues are flexible in eZiPro [108] . Indeed, binding studies using an unlinked protease-bZiPro show that peptides derived from the protease cleavage site (P1-P4 residues) bind to protease with affinities in µM-mM range [108] (Figure 4) . Such a dynamic nature and weak protease binding affinity of the residues at the cleavage site is critical for the protease's function as these residues are present in the native protease and should not interfere with the cleavage of other positions (Figure 1 ). The dynamic nature might be important for viral protease to recognize cleavage sites. Inhibitor/substrate induced conformational changes were observed in proteases of dengue, West Nile, and Zika viruses. In addition, computation-based studies also reveal the structural changes of viral proteases [125, 126] . Based on these observations, researchers have been developing compounds that were able to stabilize the inactive/open conformation [49, 127] . As the protease contains two proteins, any compounds affecting their interactions might be active against the enzymatic activity. The dynamics and conformational changes of the protease revealed by structural studies provide insights into developing protease inhibitors [128] . In summary, the dynamics of proteases is critical for function of the enzymes and provides insights into inhibitor design. First, the open and closed conformations observed in the crystal structures provide ways to develop inhibitors. Any compounds able to lock these conformations will be effective in inhibiting the enzyme activity. Second, the weak binding affinity between NS3 and P1-P4 residues, which are dynamic in solution, is critical for the enzyme to cleave other enzymatic cleave sites. Lastly, the dynamic nature of the protease might be critical for changing orientations of the protease on the membrane, which can be critical for the protease activity or other enzymatic activities of NS3.

Several strategies, such as high throughput screening (HTS), computation-guided drug design, and fragment based drug discovery have been applied to develop protease in-hibitors [129] [130] [131] [132] [133] . The available inhibitors have been reviewed thoroughly [10, 33, 117, [134] [135] [136] [137] [138] [139] . Inhibitors include substrate derived peptidic compounds, small molecules binding to the active site and allosteric inhibitors ( Figure 5 ) [11] . Due to the presence of conformational exchanges in the protease and low druggability of the protease active site [89] , developing the allosteric inhibitor is of great interest and potent allosteric inhibitors have been developed [50, 118, 140, 141] . As this type of inhibitor exhibited antiviral activity in cell-based assays, it has great potential in being developed into antivirals. 

Inhibitors derived from the substrate have been developed and well-characterized [142] [143] [144] . These peptidic inhibitors can grouped into three classes: covalent peptidic inhibitors, cyclic peptides, and normal peptides. Covalent peptidic inhibitors are the dominant ones and contain three important regions-the backbone derived from the substrate sequence interacting with the S1-S2/S3 sites, the cap region enhancing the activity by forming interactions with residues outside of S1 and S2/S3 sites, and a warhead at the C-terminus, such as aldehyde and boronic acid forming a covalent bond with residue S135 [93, [145] [146] [147] . One of the most characterized peptidic inhibitors is a tetrapeptide inhibitors-nKRR-aldehyde, which exhibited a wide-spectrum activity against flavivirus proteases [59, 60, 116] . Extensive studies, on, e.g., optimizing the competent of the peptide sequence using different amino acids, adopting various warheads, and shortening or increasing the length of the peptide, have been carried out to improve the potency of inhibitors [148, 149] . The peptidic inhibitor with the smallest molecule weight is Ac-KR-aldehyde in which two amino acids are present [60] . Inhibitors that are cyclic peptides can be developed from the substrates and identified from screening. This type of inhibitor usually contains more than three amino acids. The cyclic peptides can be more stable than normal peptides under physiological conditions. It is possible to develop both competitive and noncompetitive cyclic peptides, while extensive studies are needed to improve the potency [57, 119] . Developing linear peptides active against the ZIKV protease will be challenging, while a small protein bovine pancreatic trypsin inhibitor (BPTI) is active against proteases from several viruses [58] . Despite efforts being made in drug discovery, there are still no peptidic inhibitors suitable for further studies, which is due to the fact that the charged residues at the P1 and P2 positions cannot be replaced [116] . Therefore, the peptidic inhibitor exhibited potent inhibitory activity against ZIKV protease while challenges in stability in vivo and penetrating the cell membrane make them difficult for clinical studies. Peptides that can be utilized in clinical studies need to be developed [10, 119] .

Although it is challenging to develop peptidic inhibitors, quite a few completive and noncompetitive peptidic inhibitors are available. The following strategies might be useful to develop antivirals derived from peptides. First, adoption of unnatural amino acids in inhibitors. Second, exploring cyclic peptidic inhibitors is a feasible strategy to improve the properties of the inhibitors. Third, linking peptidic inhibitors with small molecules might be a promising strategy while extensive structural studies are needed. Lastly, allosteric peptidic inhibitors are of great interest while structural studies are important for elucidating the mechanism of action.

Strategies, such as virtual screening and HTS campaigns, have been applied to identify small molecule inhibitors [129, 150] . Although quite a few inhibitors are available [150, 151] , no compound has reached clinical studies. Due to the hydrophilic nature of the protease, these small-molecule inhibitors that bind to the active site are not as potent as peptidic inhibitors, unless they form a covalent bond with the protease. The following types of small molecules are developed. First, some small-molecule inhibitors are developed using conventional methods, such as HTS and structure-based design. Quite a few fragments were identified and shown to bind to the substrate-binding site while further fragment optimization is needed to improve the potency [57, 102] . Second, developing irreversible inhibitors is a strategy to identify competitive inhibitors. An irreversible inhibitor was shown to be effective in inhibiting the Zika protease by forming covalent interactions with Ser135 [59, 152] . Structural studies and mass spectrometry analysis revealed that a portion of the compound formed a covalent bond with S135. Despite its potency against protease activity, this compound is still difficult for clinical studies due to its stability. Third, allosteric inhibitors can be developed targeting ZIKV protease. Several inhibitors were reported to inhibit protease inhibitors through allosteric or noncompetitive manners. These inhibitors were predicted to interact with a druggable site [50, 118, 153] . Recent reports show that a series of 2,5.6-trisubsitituted pyrazine compounds are potent Zika protease inhibitors by regulating the enzymatic activity through an allosteric mechanism. The nanomolar IC 50 observed in the biochemical assay and low micromolar EC68 observed in the cell-based assay suggested that these compounds have great potency to be applied in clinical studies [50]. The available crystal structure of an allosteric inhibitor bound to dengue protease proves its mode of action [50, 52] . An assay was developed to screen allosteric inhibitors. This assay was based on the presence of the open and closed conformations in ZIKV protease. As the C-terminal region of NS2B exhibits conformational changes, a conformational switch assay was developed. Several allosteric inhibitors were screened using this assay. An identified inhibitor-NSC135618 was shown to be an allosteric inhibitor with a broad spectrum [154] . The allosteric inhibitors have great potential to be developed into antivirals as they exhibited activity in cell-based assays. Structural studies and biophysical studies are still required to understanding their binding modes. Lastly, drug repurposing was applied to identify ZIKV protease inhibitors [52] . Several drugs were shown to be active against the ZIKV protease, while it is challenging to further optimize these drugs without structural information.

Protease inhibitors can be developed using strategies, such as HTS, fragment-based drug design, drug repurposing, and structure-based drug design. Due to the hydrophilic nature of the substrate-binding site, designing allosteric inhibitors is a feasible strategy to develop antivirals against ZIKV infection. It important to have an assay available to identify noncompetitive/allosteric molecules. Structures and dynamics of the protease in complexes with compounds will be critical for optimization. With novel strategies utilized in compound screening and compound optimization, more potent Zika protease inhibitors will be obtained [104, 133, 141, [155] [156] [157] .

Several ZIKV protease inhibitors have been designed while no compound has been reached into clinical studies. Different types of screening strategies including HTS using biochemical and cell-based assays, fragment-based screening, drug repurposing and virtual screening and structure-guided drug design have been utilized to identify potent protease inhibitors [10, 11, [158] [159] [160] . Nonetheless, some compounds active in biochemical assays did not exhibit any activity in cell-based assays [161] . Although this can be attributed to the chemical properties of the compounds, suitable assays in evaluating protease activity and probing protein-ligand interactions will be important in this field. There are three artificial constructs available for ZIKV protease [33], but the native form of ZIKV protease might be needed for evaluating the activity of the inhibitor and the screening of a compound from the compound library. An assay that can measure the protease and ligand binding in living cells is also helpful for evaluating and identifying new inhibitors [154] .

The protease contains some regions with exchanges, which are important for the protease function and for designing potent compounds [154, 162] . The P1-P4 residues at the native protease cleavage site at the joint of NS2B and NS3 is dynamic in solution, giving rise to empty the protease pocket for interacting with other sites. Therefore, developing a compound that can stabilize the active form with the active site occupied is a good strategy to develop inhibitors [10, 11, 52] . As aforementioned, this strategy is challenging due to the low druggability of the protease active site. The dynamic feature of the protease makes it possible to develop allosteric inhibitors, which are able to stabilize the inactive conformation and destabilize the active conformation. A recent study demonstrated the feasibility of this strategy [50, 52, 118, 153] . With the availability of structural information by X-ray crystallography, dynamic analysis by solution NMR spectroscopy, computational analysis, biochemical assays, and cell-based assays, developing allosteric inhibitors is an effective and promising strategy in antiviral development.

Quite a few viral proteins, such as ZIKV protease, possess regions that are dynamic in nature, which is critical for their functioning. Such dynamic information provides a clue for rational inhibitor design. To obtain accurate structural and dynamic information, the following factors need to be considered: a suitable construct for in vitro studies, an appropriate assay for measuring activity, a sensitive analytical tool to understand dynamics, and a cell-based assay to validate the observations. With the accumulated structural information of viral proteins and developed computational methods, the dynamics of viral proteins will be considered in rational drug design. More allosteric inhibitors can be developed by rational design. 

Zika virus. I. Isolations and serological specificity

Mitigating Prenatal Zika Virus Infection in the Americas

Zika Virus as a Cause of Neurologic Disorders

Guillain-Barre syndrome associated with Zika virus infection

Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: A case study

Zika Virus Disease: Case Report and Review of Literature. Pediatric Emerg. Care

Zika Virus Replicons for Drug Discovery

Cysteine Disulfide Traps Reveal Distinct Conformational Ensembles in Dengue Virus NS2B-NS3 Protease

Therapeutic Applications of Peptides against Zika Virus: A Review

Proteases from dengue, West Nile and Zika viruses as drug targets

Complete coding sequence of zika virus from a French polynesia outbreak in 2013

Complete Genome Sequence of a Zika Virus Strain Isolated from the Serum of an Infected Patient in Thailand in 2006

The 3.8 A resolution cryo-EM structure of Zika virus

Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion

Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease

Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein

Mapping the Interactions between the NS4B and NS3 proteins of dengue virus

Structure-based mutational analysis of the NS3 helicase from dengue virus

2 -O methylation of internal adenosine by flavivirus NS5 methyltransferase

Functional analysis of two cavities in flavivirus NS5 polymerase

Mutagenesis of the dengue virus type 2 NS5 methyltransferase domain

Dengue virus RNA polymerase NS5: A potential therapeutic target?

Amino Terminal Region of Dengue Virus NS4A Cytosolic Domain Binds to Highly Curved Liposomes

Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A

Genetic interaction between NS4A and NS4B for replication of Japanese encephalitis virus

Dengue virus NS4A cytoplasmic domain binding to liposomes is sensitive to membrane curvature

Mutational analysis of the West Nile virus NS4B protein

Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors

Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease

Crystal structure of unlinked NS2B-NS3 protease from Zika virus

Structure of the NS2B-NS3 protease from Zika virus after self-cleavage

Structural Insights into the Inhibition of Zika Virus NS2B-NS3 Protease by a Small-Molecule Inhibitor

Structural Dynamics of Zika Virus NS2B-NS3 Protease Binding to Dipeptide Inhibitors

Structural characterization of the linked NS2B-NS3 protease of Zika virus

NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease

Solution conformations of a linked construct of the Zika virus NS2B-NS3 protease

The dengue virus NS2B-NS3 protease retains the closed conformation in the complex with BPTI

NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease

Binding mode of the activity-modulating C-terminal segment of NS2B to NS3 in the dengue virus NS2B-NS3 protease

Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus

Dengue virus non-structural protein 1: A pathogenic factor, therapeutic target, and vaccine candidate

Secondary Structure and Membrane Topology of the Full-Length Dengue Virus NS4B in Micelles

Characterization of dengue virus NS4A and NS4B protein interaction

Membrane topology of NS2B of dengue virus revealed by NMR spectroscopy

Secondary structure and membrane topology of dengue virus NS4B N-terminal 125 amino acids

Determinants of Dengue Virus NS4A Protein Oligomerization

Allosteric Inhibition of the NS2B-NS3 Protease from Dengue Virus

Targeting the protease activity of Dengue virus NS3

Towards the design of antiviral inhibitors against flaviviruses: The case for the multifunctional NS3 protein from Dengue virus as a target

Cleavage preference distinguishes the twocomponent NS2B-NS3 serine proteinases of Dengue and West Nile viruses

Nile Virus NS2B/NS3 protease as an antiviral target

An inhibition model of BPTI to unlinked dengue virus NS2B-NS3 protease

Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro

Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors

Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B

Shaping the flavivirus replication complex: It is curvaceous!

The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity

The ER membrane protein complex is required to ensure correct topology and stable expression of flavivirus polyproteins

Composition and Three-Dimensional Architecture of the Dengue Virus Replication and Assembly Sites

Molecular Insights into the Flavivirus Replication Complex

Proteases in Mosquito Borne Diseases: New Avenues in Drug Development

Conformational selection in the flaviviral NS2B-NS3 protease

Expression, purification of Zika virus membrane protein-NS2B in detergent micelles for NMR studies

Crystal structure of the NS3 protease-helicase from dengue virus

Structure of West Nile virus NS3 protease: Ligand stabilization of the catalytic conformation

Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease

Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease

Ligand-bound structures of the dengue virus protease reveal the active conformation

The Structure of the Zika Virus Protease, NS2B/NS3(pro)

Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain

NMR Analysis of a Novel Enzymatically Active Unlinked Dengue NS2B-NS3 Protease Complex

Potential Dual Role of West Nile Virus NS2B in Orchestrating NS3 Enzymatic Activity in Viral Replication

Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A

Mutagenesis of D80-82 and G83 residues in West Nile Virus NS2B: Effects on NS2B-NS3 activity and viral replication

Identification and structural characterization of small molecule fragments targeting Zika virus NS2B-NS3 protease

Binding of low molecular weight inhibitors promotes large conformational changes in the dengue virus NS2B-NS3 protease: Fold analysis by pseudocontact shifts

Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics

Capturing conformational States in proteins using sparse paramagnetic NMR data

Cis autocatalytic cleavage of glycine-linked Zika virus NS2B-NS3 protease constructs

Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus

Characterization of molecular interactions between Zika virus protease and peptides derived from the C-terminus of NS2B

Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease

Insights into Structures and Dynamics of Flavivirus Proteases from NMR Studies

Determining druggability

Druggability assessment of precursor membrane protein as a target for inhibiting the Zika virus

Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics

Druggability Assessment for Selected Serine Proteases in a Pharmaceutical Industry Setting

DoGSiteScorer: A web server for automatic binding site prediction, analysis and druggability assessment

Exploring the binding of peptidic West Nile virus NS2B-NS3 protease inhibitors by NMR

Drug design for flavivirus proteases: What are we missing?

Curcumin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting Its Active Conformation

De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease

Docking of noncompetitive inhibitors into dengue virus type 2 protease: Understanding the interactions with allosteric binding sites

Lyso-myristoyl phosphatidylcholine micelles sustain the activity of Dengue non-structural (NS) protein 3 protease domain fused with the full-length NS2B

Expression, purification, and initial structural characterization of nonstructural protein 2B, an integral membrane protein of Dengue-2 virus, in detergent micelles

pH and non-covalent ligand binding modulate Zika virus NS2B/NS3 protease binding site residues: Discoveries from MD and constant pH MD simulations

Sensitive NMR Approach for Determining the Binding Mode of Tightly Binding Ligand Molecules to Protein Targets

MD simulations reveal alternate conformations of the oxyanion hole in the Zika virus NS2B/NS3 protease

Binding recognition of substrates in NS2B/NS3 serine protease of Zika virus revealed by molecular dynamics simulations

Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: Inhibition kinetics and docking studies

Intermolecular interactions of cn-716 and acyl-KR-aldehyde dipeptide inhibitors against Zika virus

The flavivirus protease as a target for drug discovery

Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses. Microorganisms 2021

Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study

Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery. Sci. Rep. 2020

Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through in-silico approaches

The Medicinal Chemistry of Dengue Virus

Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond

Nile virus drug discovery

Biochemistry and Medicinal Chemistry of the Dengue Virus Protease

Progress and prospects on DENV protease inhibitors

Cell-active carbazole derivatives as inhibitors of the zika virus protease

Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease

Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases

Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses

2-Cyanoisonicotinamide Conjugation: A Facile Approach to Generate Potent Peptide Inhibitors of the Zika Virus Protease

Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses

Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors

Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead

Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease

Exploiting Dengue Virus Protease as a Therapeutic Target; Current Status, Challenges and Future Avenues

Peptide-beta-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes

JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo

Glycyrrhetinic acid derivatives as Zika virus inhibitors: Synthesis and antiviral activity in vitro

Identification of covalent active site inhibitors of dengue virus protease

Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: In silico ligand screening and molecular dynamics studies of inhibition

A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease

Zika Virus Targeting by Screening Inhibitors against NS2B/NS3 Protease

Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease

Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches

In silico approaches to Zika virus drug discovery

Structural biology of Zika virus and other flaviviruses

Structurebased discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo

Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay

Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists